Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Novavax Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.77, while Novavax Inc trades at $7.94 (market cap $1.30B). The key difference: Novavax Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | NVAX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $11.19 |
52-Week Low | $116.45 | $6.22 |
Market Cap | — | $1.30B |
Enterprise Value | — | $800.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.76, down 0.19% with a bearish technical signal. Recent dividends include $0.36 and $0.37 payouts in mid-2026. The ETF faces headwinds from rising Treasury yields and Federal Reserve uncertainty, as bond markets react to inflation and geopolitical tensions.
Outlook remains cautious due to interest rate sensitivity; opportunities exist for low-volatility Treasury exposure, but risks include further Fed hikes and competitive pressure from higher-yielding bond ETFs like Vanguard's offerings.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
